HK Stock Movement | GIANT BIOGENE (02367) Drops Over 4% as BofA Notes Weak Double 11 Sales; Management Lowers Guidance

Stock News12-03

GIANT BIOGENE (02367) surged over 12% yesterday following a share buyback announcement but retreated more than 4% today. At press time, the stock fell 3.38% to HK$38.36, with a turnover of HK$428 million.

The company disclosed plans to exercise its share repurchase authorization, allowing it to buy back up to 103.6 million shares, or 10% of its issued shares (excluding treasury shares).

BofA Securities reported that GIANT BIOGENE faced sales pressure during the Double 11 shopping festival. According to management data, sales of the "KFM" brand on Tmall and Douyin dropped 20% and 50% year-on-year, respectively. In contrast, the "KLJ" brand achieved positive growth during the same period.

The report noted that management has lowered this year's performance guidance, expecting flat or slightly declining revenue. Net profit forecasts were also revised downward to a mid-to-high single-digit year-on-year decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment